Research Developments in Psoriasis

1.25 CME

75 MINS

$0 FEE

SAVE

Overview

Provider Statement

This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the materials, reflecting on its implications in your practice, and completing the assessment component.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Support Statement

This educational activity is supported by an educational grant from AbbVie, Janssen Biotech, Inc, administered by Janssen Scientific Affairs, LLC, and Novartis Pharmaceuticals Corp.

Target Audience

This activity was developed for dermatologists, pediatric dermatologists, and other clinicians who manage patients with moderate-to-severe plaque psoriasis.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

Summarize the latest research developments in the treatment of plaque psoriasis
Describe how new data and recommendations can impact clinical practices to improve care
Incorporate evidence-based research into clinical practice

Faculty

Steven R. Feldman, MD, PhD
Professor of Dermatology, Pathology and Public Health Sciences
Department of Dermatology
Wake Forest School of Medicine
Winston-Salem, North Carolina

Abby S. Van Voorhees, MD
Professor and Chair, Department of Dermatology
Eastern Virginia Medical School
Norfolk, Virginia

Reviewers

Greg Scott, PharmD, RPh (medical writer)
Eugene Cullen, MD (peer reviewer)

Accreditation

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How to Participate in This Activity and Obtain CME Credit

The estimated time to complete the activity is 1.25 hours.

This activity was released on June 11, 2021 and is eligible for credit through June 11, 2022.

Disclosures

It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in accredited education activities are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.

Faculty reports the following relationship(s)

In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:

Faculty

Steven R. Feldman, MD, PhD

Chief Technology Officer: Causa Technologies

Consultant: AbbVie, Advance Medical, Almirall, Alvotech, Amgen, Arena, BMS, Caremark, Celgene, Galderma Laboratories LP, Gerson Lehrman Group, Guidepoint Global, Helsinn, Janssen, Kikaku, Leo Pharma Inc, Lilly, Merck & Co, Mylan, Novartis, Ortho Dermatology, Pfizer, Regeneron, Sanofi, Sienna, Sun Pharma, Suncare Research, Xenoport

Founder: Causa Technologies

Grant Support: AbbVie, Amgen, Celgene, Galderma Laboratories LP, Janssen, Lilly, Novartis, Pfizer, Regeneron, Sanofi

Royalties: Informa, UpToDate, Xlibris

Speaker: AbbVie, Amgen, Celgene, Janssen, Leo Pharma Inc, Lilly, Leo Pharma Inc, Novartis, Ortho Dermatology, Pfizer, Regeneron, Sanofi, Sun Pharma

Stockholder: Causa Technologies, Medical Quality Enhancement Corporation

Abby S. Van Voorhees, MD

Advisory Board: BMS, Boehringer Ingelheim, Celgene, UCB

Consultant: Amgen

Investigator: AbbVie, Celgene, Lilly

Research Support: Boehringer Ingelheim

Reviewers report the following relationship(s)

Additional content planners

The following have no significant relationship to disclose:
Greg Scott, PharmD, RPh (medical writer)
Eugene Cullen, MD (peer reviewer)

Unlabeled and Investigational Usage

The faculty for this activity have disclosed that there will be discussion about the use of products for non-FDA approved indications.